补体激活产物C4d在非小细胞肺癌诊断及预后预测中的价值  

Utility of C4d in diagnosis and prognosis of patients with non-small cell lung cancer

作　　者：傅雪颜[1] 王浩[1] 吴佩卿[1] 施伟[1] 

机构地区：[1]浙江省杭州师范大学附属医院胸心外科,310015

出　　处：《中华全科医学》2014年第4期534-536,共3页Chinese Journal of General Practice

摘　　要：目的探讨补体激活产物C4d在非小细胞肺癌(NSCLC)组织中的表达及其与浸润、转移和预后的关系。方法采用酶联免疫吸附剂检测30例非小细胞肺癌患者血清中补体激活产物C4d的水平,并检测同期收治的30例肺良性病变患者血清中补体激活产物C4d水平。比较非小细胞肺癌患者血清中补体激活产物C4d与预后的关系。结果非小细胞肺癌患者中,补体激活产物C4d表达阳性的患者数量为18例,对照组中表达阳性的患者数量为4例,2组差异有统计学意义(P<0.05)。肺癌组患者术前补体激活产物C4d浓度均值为12.6 U/L,对照组患者补体激活产物C4d浓度均值为2.1 U/L,2组差异有统计学意义(P<0.05)。肺癌患者术前补体激活产物C4d浓度均值为12.6 U/L,术后补体激活产物C4d浓度均值为4.5 U/L,差异有统计学意义(P<0.05)。短期存活组(生存期小于1年)患者补体激活产物C4d浓度均值为7.3 U/L,长期存活组(生存期长于1年)患者补体激活产物C4d浓度均值为18.4 U/L,2组差异有统计学意义(P<0.05)。结论补体激活产物C4d在非小细胞肺癌患者和非良性疾病患者中表达差异显著,其生物学浓度与非小细胞肺癌患者的预后有直接联系,具有一定的临床推广意义,能作为肺癌患者早期诊断和预后预测的生物标志物。Objective To investigate the expression of complement activation product C4d in cancerous tissue of non- small cell lung cancer（ NSCLC）, and its relationship with invasion, metastasis and prognosis of patients. Methods The levels of serum C4d were determined in 30 cases of NSCLC and 30 patients with benign lung lesions by using ELISA. The relationship between C4d level and the prognosis of patients were evaluated. Results The positive rate of C4d in NSCLC group was 60% （18/30） and in benign lung lesions was 13% （4/30） , the difference was statistically significant（ P 〈 0.05 ）. The preoperative concentration of C4d was 12.6 U/L in the NSCLC group and 2.1 U/L in the benign lung lesions group,the difference was statistically significant（ P 〈 0.05 ）. In the NSCLC group, the preoperative concentration of CAd was 12.6 U/L and the postoperative concentration of C4d was 4.5 U/L, the difference was statistically significant（ P 〈 0.05 ）. The concentration of C4d was mean 7.3 U/L in the short-term survival group（ survival less than 1 year） and mean 18.4 U/L in the long-term survival group（ survival longer than 1 year）, and the difference was statistically significant （ P 〈 0.05 ）. Conclusion There is significant difference in complement activation products CAd levels between the pa- tients with NSCLC and benign lung lesions. The concentration of CAd is related to the prognosis of patients with NSCLC, which can be used as diagnostic and prognostic biomarkers for early lung cancer patients.

关 键 词：补体激活产物C4d 非小细胞肺癌 诊断 预后 

分 类 号：E734.2[军事—军事理论] R392.11[医药卫生—免疫学]